Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

ZIP and Pro Medicus Limited: 2 ASX shares to dig into

The Zip Co Ltd (ASX:ZIP) share price has jumped 429.0% since the start of 2024. It's probably worth asking, 'is the ZIP share price cheap?'
The Zip Co Ltd (ASX:ZIP) share price has jumped 429.0% since the start of 2024. The Pro Medicus Limited (ASX:PME) share price is tracking 141.6% off its 52-week lows.

ZIP share price in focus

Zip Co is a ‘fintech’ company founded in 2013. It offers a buy-now-pay-later (BNPL) service that is popular among retail consumers.

Zip’s platform allows customers to purchase items immediately and repay them over several interest-free instalments.

Like most BNPL companies, Zip makes money through transaction fees paid by the business, as well as late fees charged to customers who miss payments.

PME shares

Founded in 1983, Pro Medicus is a provider of radiology IT software serving hospitals, imaging centres and health care groups worldwide.

The company’s suite of products focuses on Radiology Information Systems (RIS), Picture Archiving and Communication Systems (PACS), and advanced visualization solutions. These tools support various functions, from patient scheduling and billing to rapid medical imaging interpretation and analysis.

ZIP share price valuation

As a growth company, one way to put a rough guesstimate on the ZIP share price could be to compare its price-to-sales multiple over time. This can tell us how the company has historically been valued relative to its total revenue.

Currently, Zip Co Ltd shares have a price-sales ratio of 4.93x, compared to its 5-year average of 5.81x, meaning its shares are trading lower than their historical average. This could mean that the share price has fallen, or sales have increased, or both. In the case of ZIP, revenue has been growing over the last 3 years. Of course, context is important – and this is just one valuation technique. Investment decisions can’t just be based on one metric, but this can be a rough starting point.

The PME share price currently trades at a price-sales ratio of 133.62x, which compares to its 5-year long-term average of 82.69x. So, its shares are trading above their historical average. Don’t forget, a simple multiple like this should only be the start of your research. The Rask websites offer free online investing courses, created by analysts explaining things like Discounted Cash Flow (DCF) and Dividend Discount Models (DDM). They even include free valuation spreadsheets! It’s a good idea to use multiple valuation methods to value a share like Pro Medicus Limited.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

5%+ in passive income

Owen Rask’s investing report available

With bond ETFs like ASX:IAF and the S&P 500 riding high, now could be one of the best times to start earning passive income from a portfolio of shares and ETFs.

In this free analyst report, our Chief Investment Officer, Owen Rask, names 10 ASX stocks and ETFs to watch.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Skip to content